![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/fda-roundup-august-20-2024-302226711.html
https://www.globenewswire.com/news-release/2024/06/03/2892527/0/en/Late-breaking-results-from-PALOMA-2-study-of-subcutaneous-RYBREVANT-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumour-response-and-improved-safety-pr.html
https://www.prnewswire.com/news-releases/late-breaking-results-from-paloma-2-study-of-subcutaneous-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumor-response-and-improved-safety-profile-in-patients-with-egfr-mutated-non-small-cell-lung-cance-302162281.html
https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazertinib-is-the-only-chemotherapy-free-regimen-showing-longer-progression-free-survival-versus-osimertinib-in-first-line-treatment-of-patients-with-high-risk-egfr-mutated-non-small-cell-lung-ca-302160976.html
https://www.prnewswire.com/news-releases/first-results-from-late-breaking-phase-3-paloma-3-study-show-five-fold-reduction-in-infusion-related-reactions-with-five-minute-subcutaneous-amivantamab-administration-302160977.html
https://www.prnewswire.com/news-releases/johnson--johnson-submits-supplemental-biologics-license-application-and-new-drug-application-to-us-fda-seeking-approval-of-rybrevant-amivantamab-vmjw-plus-lazertinib-for-the-treatment-of-patients-with-egfr-mutated-non-small--302020967.html
https://www.prnewswire.com/news-releases/landmark-phase-3-mariposa-study-shows-rybrevant-amivantamab-vmjw-plus-lazertinib-resulted-in-30-percent-reduction-in-risk-of-disease-progression-or-death-compared-to-osimertinib-in-patients-with-egfr-mutated-non-small-cell-lung-301964599.html#:~:text=MADRID%2C%20Oct.%2023%2C%202023,risk%20of%20disease%20progression%20or
https://www.prnewswire.com/news-releases/landmark-phase-3-mariposa-study-shows-rybrevant-amivantamab-vmjw-plus-lazertinib-resulted-in-30-percent-reduction-in-risk-of-disease-progression-or-death-compared-to-osimertinib-in-patients-with-egfr-mutated-non-small-cell-lung-301964599.html
https://endpts.com/jj-challenges-astrazeneca-in-lung-cancer-with-phiii-pfs-win/
https://www.prnewswire.com/news-releases/treatment-with-rybrevant-amivantamab-vmjw-and-lazertinib-plus-chemotherapy-showed-durable-progression-free-survival-in-patients-with-previously-treated-egfr-mutated-advanced-non-small-cell-lung-cancer-301923248.html
https://www.prnewswire.com/news-releases/phase-3-mariposa-2-study-meets-dual-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybrevant-amivantamab-vmjw-plus-chemotherapy-with-and-without-la-301919084.html
https://www.prnewswire.com/news-releases/janssen-announces-new-data-supporting-safety-and-efficacy-of-rybrevant-and-lazertinib-combination-for-patients-with-non-small-cell-lung-cancer-and-egfr-mutations-301593280.html
https://www.prnewswire.com/news-releases/new-data-on-rybrevant-amivantamab-vmjw-in-combination-with-lazertinib-show-early-activity-in-patients-with-non-small-cell-lung-cancer-whose-disease-has-progressed-after-both-osimertinib-and-platinum-based-chemotherapy-301380002.html
https://www.fiercebiotech.com/biotech/esmo-janssen-s-anti-egfr-combo-tackles-lung-cancer-ahead-phase-3-tagrisso-showdown